Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfs230D1 conjugate vaccine
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Pfs230D1 conjugate vaccine is a transmission-blocking malaria vaccine candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with the Serum Institute of India. The vaccine targets Pfs230, a surface antigen of Plasmodium falciparum gametocytes, gametes, and zygotes. By conjugating the first domain of Pfs230 (Pfs230D1) to carrier proteins such as Pseudomonas aeruginosa ExoProtein A (EPA) or CRM197, the vaccine induces antibodies that prevent fertilization of the parasite within the mosquito midgut, thereby blocking transmission from humans to mosquitoes. It is formulated with various adjuvants, including Alhydrogel, AS01, and Matrix-M, and is being evaluated in clinical trials for the prevention of malaria transmission.
- Other names
- Pfs230D1Pfs-230D1Pfs 230D1Pfs230D1-CRM197 conjugate vaccinePfs-230D1-CRM197 conjugate vaccinePfs 230D1-CRM197 conjugate vaccinePfs230D1-EPA conjugate vaccinePfs-230D1-EPA conjugate vaccinePfs 230D1-EPA conjugate vaccinePfs230D1-EPA/AlhydrogelPfs230D1-EPA/Matrix-MPfs230D1-ferritinPfs-230D1-ferritinPfs 230D1-ferritinPfs230D1M-EPA/AS01
02
Targets
Pfs230
Beyond the preview
Go deeper on Pfs230D1 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfs230D1 conjugate vaccine.